Perihilar intrahepatic cholangiocarcinoma is a type of intrahepatic cholangiocarcinoma — a cancer arising within the liver — that originates specifically from the large bile ducts located near the hilum of the liver. It is classified as a malignant tumor of the biliary system and falls within the broader category of liver and biliary tract cancers. This packet does not certify causative genes, age of onset, or prevalence figures for this condition. The knowledge in this report is drawn from certified database sources as of September 9, 2026.

Certified phenotype data, characteristic clinical findings, and affected organ system details are not present in this packet. As a result, a detailed description of the signs and symptoms of perihilar intrahepatic cholangiocarcinoma cannot be provided from certified sources at this time. The condition arises from intrahepatic large bile ducts near the hilum, which situates it within the biliary and hepatic systems, but specific clinical features, their frequency, or their typical pattern of presentation are not certified in this packet.

This packet does not provide a certified causative gene claim for perihilar intrahepatic cholangiocarcinoma. No genes are listed in the certified gene field, and no molecular mechanism is described in this packet. Inheritance pattern is likewise not certified here. The condition is defined as arising from the intrahepatic large bile ducts, but the underlying genetic or molecular contributors to its development are outside the scope of the information certified in this packet.

Certified diagnostic methods, biomarker thresholds, diagnostic criteria, and testing hierarchies are not present in this packet for perihilar intrahepatic cholangiocarcinoma. Newborn screening is not applicable to this condition. No differential diagnosis information is certified in this packet. Accordingly, a description of specific diagnostic approaches cannot be provided from certified sources at this time.

Foundational therapies and FDA-approved treatments are not certified in this packet. One orphan-drug designation record is present: Lytgobi holds an orphan designation — granted in 2022 — for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions. An orphan designation is a regulatory designation and is distinct from FDA approval; it does not establish that a treatment is currently approved or available for this condition.

Natural history data and prognosis information are not certified in this packet for perihilar intrahepatic cholangiocarcinoma. No certified clinical description or disease-course details are available from the sources assembled for this report. Accordingly, outlook and long-term course cannot be described from certified data at this time.

Several certified active trial records are present for perihilar intrahepatic cholangiocarcinoma. These include a recruiting study (NCT05546372) examining endobiliary radiofrequency ablation for malignant biliary obstruction due to perihilar cholangiocarcinoma, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam. A Phase II study (NCT07030140) is evaluating neoadjuvant tislelizumab combined with radiotherapy and chemotherapy for borderline or unresectable hilar cholangiocarcinoma. Another recruiting trial (NCT06986486) is investigating liver transplantation for unresectable perihilar cholangiocarcinoma, sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. Active clinical trials for this condition are listed on ClinicalTrials.gov.